Physician profile
Natalie Guinn
NPI 1235662305
$1,962.32
in general payments reported to CMS, 2019-2025
20 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $18.22 · 2021: $122 · 2022: $118 · 2023: $665 · 2024: $794 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,513 · Education: $57.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,512.94 |
| Education | $57.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $286.61 | 2021-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $199.86 | 2022-2024 | Farxiga, Lokelma |
| Ardelyx, INC. | $196.19 | 2023-2024 | Xphozah 30 Mg, Ibsrela |
| Aurinia Pharma U.S., INC. | $168.17 | 2023-2024 | Lupkynis |
| Vifor Pharma, INC. | $161.50 | 2023-2024 | Veltassa, Korsuva |
| Pfizer INC. | $134.04 | 2019 | |
| Amgen INC. | $108.35 | 2023-2024 | Tavneos, Parsabiv, Krystexxa |
| Travere Therapeutics, INC. | $105.31 | 2023-2025 | Filspari |
| Mallinckrodt Hospital Products INC. | $97.58 | 2023-2024 | Acthar |
| Baxter Healthcare | $92.22 | 2023 | Renal - Pd |
| Daiichi Sankyo INC. | $76.41 | 2022-2024 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $71.18 | 2022-2023 | |
| Akebia Therapeutics INC | $54.14 | 2024-2025 | Auryxia, Vafseo |
| Glaxosmithkline, LLC. | $52.40 | 2023-2025 | Benlysta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $44.86 | 2024-2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $39.03 | 2024 | Velphoro |
| Xeris Pharmaceuticals, INC. | $21.32 | 2024 | Keveyis |
| Calliditas Therapeutics US INC. | $19.61 | 2022 | |
| Intercept Pharmaceuticals, INC. | $18.22 | 2020 | |
| Fresenius USA Manufacturing, INC. | $15.32 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Guinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.